ストックスクリーナーアプリを入手
8.02
0.12%
0.010
Diamedica Therapeutics Inc (DMAC) 最新ニュース
Enterprise value to EBITDA forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DiaMedica Therapeutics Inc. Actuals & Estimates (NASDAQ:DMAC) - TradingView
DMAC Forecast — Price Target — Prediction for 2027 - TradingView
DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43% - simplywall.st
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - BioSpace
DiaMedica Therapeutics (DMAC) Initiates Phase 2 Trial for DM199 in Fetal Growth Restriction - GuruFocus
DiaMedica doses first patients in fetal growth restriction trial - Investing.com
DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating - Moomoo
DiaMedica Therapeutics Inc (DMAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DiaMedica Therapeutics Inc (DMAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
DiaMedica Therapeutics Inc (DMAC) Valuation: PE, PB & Fair Value Analysis - TradingKey
DiaMedica Therapeutics Inc (DMAC) Institutional Confidence - TradingKey
DiaMedica Therapeutics Inc - TradingKey
DiaMedica Therapeutics Inc (DMAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DiaMedica Therapeutics receives written response from FDA on DM199 - TipRanks
DiaMedica Therapeutics (DMAC) Updates on FDA Response for DM199 Development - GuruFocus
DiaMedica to conduct rat study addressing FDA data request - Investing.com
DiaMedica to conduct rat study addressing FDA data request By Investing.com - Investing.com Canada
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
DiaMedica Therapeutics (DMAC) Hovers Near Key Support After Slight PullbackGrowth Stock Picks - newsline.com
DMAC Q1 2026 Earnings: Clinical Progress Drives Optimism Despite Slight EPS MissEarnings Miss Streak - newsline.com
DiaMedica Therapeutics (DMAC) Gains 3.66% as Biotech Stock Tests Key Resistance ZonePut Spread Alert - newsline.com
DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84 - Stock Titan
DiaMedica (DMAC) director Richard Kuntz receives grant of 40,412 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) director granted 40,412-share stock option award - Stock Titan
DiaMedica (DMAC) director Tanya Lewis awarded 40,412 stock options at $5.84 - Stock Titan
DiaMedica Therapeutics (DMAC) director receives 40,412-share stock option grant - Stock Titan
DiaMedica Therapeutics (NASDAQ: DMAC) director receives grant of 51,189 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CEO awarded 380,000 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CFO awarded 162,000 stock options at $5.84 strike - Stock Titan
DiaMedica Therapeutics (DMAC) CMO receives 67,500 stock options expiring 2036 - Stock Titan
DiaMedica Shares Down Ahead of Stroke Trial Update - Bez Kabli
DiaMedica (DMAC) Q4 2025 Earnings Transcript - The Globe and Mail
DMACDiaMedica Therapeutics Inc Latest SEC Filings - Finviz
DiaMedica Therapeutics (DMAC) Slides 2.76% as Biotech Sector Headwinds Pressure Small-Cap NamesWave Equality - The Legal Advocate
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - BioSpace
DMAC Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline AdvancesProfit Guidance Range - The Legal Advocate
DiaMedica Therapeutics (DMAC) Gains 4% as Stock Approaches Key Resistance LevelCumulative Volume - The Legal Advocate
DiaMedica Therapeutics (DMAC) Gains 2.43% as Buyers Defend Key SupportSynthetic Long - The Legal Advocate
DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan - The Globe and Mail
DMAC Q1 2026 Earnings: Wider Loss Than Expected as Clinical Pipeline AdvancesFinancial Health Score - thelegaladvocate.com
DiaMedica Therapeutics (NASDAQ: DMAC) investors approve directors, pay and 3.5M-share incentive plan boost - Stock Titan
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - BioSpace
DiaMedica stroke trial reaches 75% of interim analysis threshold By Investing.com - Investing.com South Africa
DiaMedica stroke trial reaches 75% of interim analysis threshold - Investing.com India
DiaMedica Therapeutics (DMAC) Advances in Pivotal Trial Enrollme - GuruFocus
DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment - marketscreener.com
Diamedica Therapeutics announces 75% enrollment milestone in Remedy2 phase 2/3 acute ischemic stroke trial - marketscreener.com
Why Is DiaMedica Therapeutics Inc. (DMAC) Stock Down Today? - Meyka
1.95%
2.70%
大文字化:
|
ボリューム (24 時間):